idursulfase-IT

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

72 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

1

Exelon

Novartis

Approved

52

Ritalin

Novartis

Approved

33

Cymbalta

Jazz Pharmaceuticals

Approved

14

Aldactone

Pfizer

Approved

15

Brintellix

Takeda

Approved

—6

Marinol

Jazz Pharmaceuticals

Approved

—7

Intropin

Pfizer

Approved

—8

Glucophage

EMD Serono

Approved

39

Lithobid

SSolvay Pharmaceuticals

Approved

210

Coumadin

AAbbott

Approved

1Show 43 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cognitive impairment3 trials

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Active, not recruiting·Takeda·Phase 2/3·NCT06031259·6 enrolled

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

Completed·Takeda·Phase 1/2·NCT01506141·15 enrolled

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Completed·Takeda·Phase 2/3·NCT02055118·58 enrolled

Treatment1 trial

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Completed·Takeda·Phase 2/3·NCT02412787·56 enrolled

Hunter Syndrome1 trial

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Available·Takeda··NCT05795361

Details

Drug Info

Related News